Johnson & Johnson Reports Q4 and Full-Year 2022 Results
NEW BRUNSWICK, N.J. – January 24, 2023 – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. “Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value...
Source: Johnson and Johnson - January 24, 2023 Category: Pharmaceuticals Source Type: news

What to Know About Infusion Therapy for IBD
The human gastrointestinal tract can be a hostile place for visitors. It’s filled with digestive acids and microorganisms that rapidly break down swallowed bits of food, and it can be just as rough on non-food molecules. That includes some of the latest drugs for the treatment of inflammatory bowel disease (IBD). “Some medications that target the immune system don’t work if they’re swallowed because your gut would digest them like a piece of steak,” says Dr. Gilaad Kaplan, a gastroenterologist, IBD researcher, and professor of medicine at the University of Calgary in Canada. “You have to...
Source: TIME: Health - January 10, 2023 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Source Type: news

IBD: Limited Protection Against Omicron With Third Vaccine Dose IBD: Limited Protection Against Omicron With Third Vaccine Dose
Patients with IBD taking infliximab or tofacitinib may be more vulnerable to Omicron infection even after a third dose of a COVID-19 mRNA vaccine.MDedge News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - January 9, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Infliximab Maintenance Home Infusion Appears Safe
(MedPage Today) -- ORLANDO – Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, a researcher reported here. Of 863 patients... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - December 7, 2022 Category: Gastroenterology Source Type: news

Retention High With Biosimilar-to-Biosimilar Switch for Arthritis Retention High With Biosimilar-to-Biosimilar Switch for Arthritis
Danish investigators studied how a government-mandated switch from one infliximab biosimilar to another affected patients with inflammatory arthritis.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 15, 2022 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Anti-Inflammatory Agents May Have Role in COVID-19 Pneumonia
(MedPage Today) -- WASHINGTON -- Use of the anti-inflammatory agents infliximab (Remicade) and abatacept (Orencia) added to standard of care showed a hint of improvement in outcomes for patients hospitalized with COVID-19 pneumonia, according... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - October 25, 2022 Category: Infectious Diseases Source Type: news

Infliximab in Patients With Juvenile-Onset Spondyloarthritis Infliximab in Patients With Juvenile-Onset Spondyloarthritis
Is infliximab an effective therapeutic option for patients with juvenile-onset spondyloarthritis who don ' t adequately respond to conventional treatment?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 25, 2022 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Johnson & Johnson Reports Q3 2022 Results
New Brunswick, N.J. (October 18, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2022. “Our third quarter performance demonstrates our continued strength and resilience across all three of our businesses,” said Joaquin Duato, Chief Executive Officer. “Through the ongoing efforts of our teams around the world, we continue to navigate the dynamic macroeconomic environment and remain focused on delivering transformative healthcare solutions. Looking ahead, I remain confident in our business and ability to continue advancing our innovative portfolio and pipeline.”OVERALL FINANCIAL ...
Source: Johnson and Johnson - October 18, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news

Low Risk for IBD Relapse After Switch From IV to Subcutaneous Infliximab
(MedPage Today) -- Switching from intravenous to subcutaneous infliximab (Remicade) was safe and effective for patients with inflammatory bowel disease (IBD) in clinical remission, an observational study in France showed. Among 133 patients treated... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - August 19, 2022 Category: Gastroenterology Source Type: news

Snoring & Liver Disease; Remicade's COVID Woes; Delays in Liver Cancer Treatment
(MedPage Today) -- What's the link between snoring and fatty liver disease? (Journal of Clinical Endocrinology & Metabolism) An appeals court sided with AbbVie, saying the company's 132 patents related to its inflammatory bowel disease (IBD... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - August 4, 2022 Category: Gastroenterology Source Type: news

Johnson & Johnson Reports Q2 2022 Results
New Brunswick, N.J. (July 19, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2022. “Our solid second quarter results across Johnson & Johnson reflect the strength and resilience of our Company’s market leadership in the midst of macroeconomic challenges,” said Joaquin Duato, Chief Executive Officer. “I am continually energized by the focus and passion of my Johnson & Johnson colleagues and their dedication toward delivering transformative healthcare solutions to patients and consumers around the world.”OVERALL FINANCIAL RESULTS expand ...
Source: Johnson and Johnson - July 19, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news

Johnson & Johnson Reports Q1 2022 Results
New Brunswick, N.J. (April 19, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2022. “Our first quarter results demonstrate strong performance across the enterprise, despite macro-economic headwinds. I am incredibly proud of Johnson & Johnson’s 144,000 employees for their relentless passion and Credo-based commitment to delivering transformative healthcare solutions to patients and customers around the world,” said Joaquin Duato, Chief Executive Officer. “Looking ahead, I remain confident in the future of Johnson & Johnson as we continue advancing our portfolio and inno...
Source: Johnson and Johnson - April 19, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news

Endoscopic Healing of Crohn's Disease Could Differ by Biologic Endoscopic Healing of Crohn's Disease Could Differ by Biologic
Infliximab biosimilar and adalimumab resulted in better endoscopic healing rates than either vedolizumab or ustekinumab in a post hoc pooled analysis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 3, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Industry Payments Linked With Rheumatologists' Prescribing Industry Payments Linked With Rheumatologists' Prescribing
For every $100 in food/beverage payments, the probability of prescribing increased from 1.5% to 14% for most drugs. The increase was particularly high for infliximab and rACTH.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 24, 2022 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Meta-Analysis Favors SubQ Infliximab Over Vedolizumab in Crohn's Meta-Analysis Favors SubQ Infliximab Over Vedolizumab in Crohn's
Researchers evaluated results of seven major studies to compare efficacy and safety of the two agents in Crohn ' s disease and ulcerative colitis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - February 23, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news